15 Nov 2013
What Speech-Language Pathologists Need to Know About the Emerging Medical Treatments in Stuttering (Ep. 429)
Gerald A. Maguire, MD joins Peter Reitzes to discuss what speech-language pathologists need to know about the emerging medical treatments in stuttering.
StutterTalk is excited to announce that this StutterTalk episode or course will be available for 0.10 CEUs for approximately six months, free of charge, through the National Stuttering Association. For complete details regarding the continuing education units being offered by the National Stuttering Association, go to the National Stuttering Association’s CEU page.
Title: What Speech-Language Pathologists Need to Know About the Emerging Medical Treatments in Stuttering
Objectives: At the conclusion of the program, the learner shall be able to:
- Identify the new DSM 5 criteria for childhood onset fluency disorder (stuttering)
- Summarize available pharmacologic treatments for stuttering and related conditions.
- Cite how traditional speech therapy with people who stutter is commonly effected by the medical treatment of stuttering.
Presenter Bio — Gerald A. Maguire, MD, is Sr. Associate Dean of Medical Education, holds the Kirkup Endowed Chair in Stuttering Treatment and is Professor of Clinical Psychiatry at the University of California Irvine School of Medicine. Dr. Maguire is a regular guest on StutterTalk. His previous appearances are archived here. Contact Dr. Maguire directly via email: firstname.lastname@example.org.
Episode/Course Description: Stuttering has recently been reclassified in DSM 5 as Childhood Onset Fluency Disorder. Over the past decade, much has been learned regarding the neurophysiologic and genetic basis of stuttering. With such, methods for medical treatments have emerged. Such treatments can potentially be utilized when standard speech therapy techniques have not yielded full benefits or as an augmentation to such treatments.
Presenter’s Financial Disclosures: Research Grants: Otsuka, Merck. Speaking/Consulting: Lilly, Novartis, Merck, Sunovion, Assurex, Lundbeck, Otsuka, Takeda